n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea has been researched along with Adrenal Hyperplasia, Congenital in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Auchus, RJ; Chang, AY; El-Maouche, D; Joyal, EG; Lin, VH; Merke, DP; Mohideen, P; Plaunt, MR; Turcu, AF; Vogiatzi, MG; Weintraub, L | 1 |
Speiser, PW | 1 |
1 trial(s) available for n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea and Adrenal Hyperplasia, Congenital
Article | Year |
---|---|
A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Administration, Oral; Adolescent; Adrenal Cortex; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Adult; Androstenedione; Biomarkers; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucocorticoids; Humans; Middle Aged; Treatment Outcome; Urea; Young Adult | 2020 |
1 other study(ies) available for n-(2,6-bis(isopropyl)phenyl)-n'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea and Adrenal Hyperplasia, Congenital
Article | Year |
---|---|
Invited Commentary: A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Humans; Urea | 2020 |